February 25, 2013
Posted by on
Welcome to your Monday Biotech Deal Review for February 25, 2013!
This week saw significant activity on the investment front. Stem Cell Therepeutics and Sirona have each indicated an intention to raise funds through private placements, while Oncolytics Biotech is aggressively hoping to raise $32 million through a public offering. Sernova, Helix BioPharma and Amforfix have each closed their own private placements this week as well. On the M&A front, Cangene has closed their acquisition of the hemophilia compound IB1001, acquiring it through Inspiration Biopharmaceutical’s bankruptcy.
There’s more great stories this week, so click onward to see the whole week’s Deal Review.
Read more of this post
September 19, 2011
Posted by on
Welcome to your Monday Biotech Deal Review for September 19, 2011. Of note in the past week was the extension of the hostile bid by Paladin Labs of Afexa Life Sciences to September 28th, the application by Merus to graduate to the TSXV, and the filing by Allon Therapeutics of a short-form preliminary prospectus. Read on to learn more. Read more of this post
February 11, 2009
Posted by on
Deep Appreciation:for Phillip Terrence Ragon, founder and sole proprietor of database-software provider InterSystems who donated $100 million to establish a research institute that focuses on expediting the development of an AIDS vaccine, and to Pfizer Canada which contributed a further $2 million to British Columbia’s Center for Drug Research and Development (CDRD); and The State of Georgia is contemplating a $180 million bioscience research park.
Social Agitation: French scientists decided their street protests were their best approach to halting the government’s science and higher education reforms and rejected mediation.
Better Cogitation:Brain-Derived Neurotrophic Factor (BDNF) shows neuroprotective effects in animal models of Alzheimers’, but it won’t stop cries of ‘brain drain’ following Canada’s 2009 Budget.
Free Publication: ScienceInsider reports that Rep. Conyers’ (D-MI) bill that would eliminate free full-text publication of NIH-funded research is back on the table this session.
Self Regulation:More Pharma companies are implementing voluntary disclosure of physician payments (under threat of legislation); and some researchers are taking steps to prevent disclosures of potentially harmful research (under threat of annihilation).
Reconsideration: Researchers at Emory decided that flu pandemic deaths in 1918 may have been primarily from bacterial superinfections rather than the virus itself; Icahn decided to nominate another slate of Biogen-Idec directors; Everybody decided to take another look at their luciferase screening assay controls; and the Ontario Health Insurance Plan (OHIP) decided to take another look at payment for PSA testing for prostate cancer detection.